What to Do if Insurance Denies Your GLP-1?
Last updated: January 2026
Quick Answer
File a formal appeal with your insurer. Get a letter of medical necessity from your doctor. If denied again, request an external review. Meanwhile, compounded alternatives at $149-299/month are a practical backup.
What to Do if Insurance Denies Your GLP-1
File a formal appeal with your insurer. Get a letter of medical necessity from your doctor. If denied again, request an external review. Meanwhile, compounded alternatives at $149-299/month are a practical backup.
Insurance coverage for GLP-1 medications has expanded significantly in recent years, driven by growing clinical evidence and the FDA's cardiovascular risk reduction approval for semaglutide. However, coverage varies widely between insurance plans, employers, and states.
How to Check Your Coverage
The most reliable way to check GLP-1 coverage is to call the number on the back of your insurance card and ask specifically about weight management medications. Request information about your plan's formulary, prior authorization requirements, and any step therapy protocols.
What If You Are Not Covered?
- File an appeal with documentation of medical necessity
- Ask your provider about peer-to-peer review with the insurance medical director
- Consider compounded GLP-1 through a telehealth provider ($149-449/month)
- Use HSA/FSA pre-tax funds regardless of insurance coverage
- Check manufacturer patient assistance programs for brand-name options
Even without insurance coverage, compounded GLP-1 medications through telehealth providers are often more affordable than the copay on brand-name drugs with insurance.
Related Questions
What Is Prior Authorization for GLP-1 Medications?
Prior authorization requires your doctor to submit clinical documentation proving medical necessity before the insurer approves coverage.
What is the Difference Between Compounded and Brand Semaglutide?
Same active molecule (semaglutide). Brand-name (Wegovy/Ozempic) comes from the original manufacturer in a standardized pen. Compounded versions are made by 503A/503B pharmacies, often in vials, at 80-85% lower cost. Clinical outcomes appear comparable when properly dosed.